SynthesisFrontiers in aging2025
The influence of circulating cholesterol and its components in middle-aged adults on cognitive function at mid- and later-life; a systematic review.
Synthesis in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Several measures of cardiovascular health have been investigated as potential risk factors for development of cognitive decline in mid-to later-life, among them, circulating cholesterol. However, the efficacy of midlife interventions aimed at reducing blood cholesterol to mitigate the risk of cognitive decline is uncertain, with conflicting evidence reported from a range of longitudinal and cross-sectional studies. This review systematically investigates the connection between cholesterol measures in midlife and their impact on cognitive function in both mid- and later-life. Methods: Electronic databases were explored from their inception until December 2023. Studies that evaluated the relationship between cholesterol and its sub-components in midlife (40-65 years) and cognitive function in mid and/or later-life were included. Qualitative analysis was used to assess the associations between cholesterol and cognition according to cognitive domains (positive, negative, or neutral). Results: 106 studies were included. We found inconsistent reporting on the association between midlife cholesterol and its sub-components, and cognitive function in older age. Longitudinal cohort studies (75%) generally showed no significant link between midlife cholesterol metrics and later-life cognitive domains. Conversely, half of individual cohort studies (50%) reported negative associations with memory, executive function, global cognition, and psychomotor speed. Most studies (78.6%) found no clear relationship between midlife cholesterol metrics and cognitive function either at midlife or later life, irrespective of study design or quality. Discussion: Our review found no conclusive link between midlife cholesterol and cognitive function in mid- and later-life, contrasting with the recent inclusion of high-LDL cholesterol as a modifiable risk factor for dementia by the 2024 Lancet Commission, following its exclusion in 2020 due to lack of evidence. These conflicting reports highlight the need to continue to investigate the importance of cholesterol metrics at midlife on cognitive function throughout the lifespan. Meanwhile, efforts to manage the all of cognitive decline in mid- and later-life across the population should continue to focus on other modifiable variables. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42021238293.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.